Developing novel treatments for mental health via psychedelic therapies...

Woke Pharmaceuticals is on a mission to change the status quo in the treatment of mental health.

Woke is focused on working with leading universities and research institutes to develop psychedelic therapies to help those who struggle with mental health.

We are committed to Innovation


In addition to developing proprietary synthetic psilocybin formulations, we are pioneering novel drug discovery.

To improve patients' psychedelic experience, we are developing dosing and delivery methods for psychedelics.

The company is pursuing global patents at every opportunity, with a foundational provisional patent application already filed and many more on the way.

Latest Announcements

Press Release

UNIVERSITY OF WESTERN AUSTRALIA DISCOVERS NEW LSD COMPOUNDS

Read More
Press Release

ETHICS APPROVAL RECEIVED FOR WORLD FIRST PHASE II TRIAL

Read More
Media

Australia is about to legalise MDMA and psilocybin for medicinal use. So how will it work?

Read More
Press Release

Woke Enters Clinical Agreement with Curtin University to Evaluate WP002 Psilocybin for Chronic Pain

Read More

Research & Development

Initial focus on psilocybin for depression based on evidence of efficacy. Proprietary formulations to enhance release profile of active drug and secure Intellectual Property

CandidateMoleculeDeliveryIndicationDevelopment StatusPartners
WP001Psilocybin (low dose)Rapid release CapsuleModerate DepressionEthics approval received for Phase IIB trial Macquarie University
WP002Psilocybin (high dose)Rapid release TabletTreatment-Resistent DepressionEthics approval received for Phase IIB trial Imperial College London Drug Science (UK) Swinburne University
WP002Psilocybin (high dose)Rapid release TabletAlcohol use disorderEthics approval received for Phase IIB trial University of Sydney
WP002Psilocybin (high dose)Rapid release TabletProlonged griefEthics submission for Phase II feasibility trial in progress QIMR-Berghofer
WP002Psilocybin (high dose)Rapid release tabletChronic musculoskeletal painEthics submission for Phase II trial in Q2 CY2023 Curtin University
WP003LSD (novel analogue)EnhancedAnxiety, Substance Abuse, PTSDDrug discovery – in-vitro data H1 CY2023 University of Western Australia

Partnerships with leading clinicians and formulation experts

The Market | Unmet Medical Need Continues to Grow


Over 700 million people are affected globally with some sort of mental illness, eg: depression, anxiety, PTSD, addiction or eating disorder

Source: The World Health Organisation

Global economic costs due to mental heath disorders estimated to be USD$800 Billion direct and US$1.7 Billion indirect

Source: National Centre for Biotechnology Information

1 IN 4 PEOPLE WILL SUFFER MENTAL HEALTH DISORDERS

25% of adults in the world will be affected by mental or neurological disorders at some point in their lives

Source: World Health Organisation

ACN: 651 290 729

Address: Suite 301, 10 Bridge St, Sydney NSW 2000 Australia

Email: info@wokeph.com